US Patent Issued to Ablynx on April 29 for "Polypeptides antagonizing Wnt signaling in tumor cells" (Belgian, Austrian Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,493, issued on April 29, was assigned to Ablynx N.V. (Zwijnaarde, Belgium).

"Polypeptides antagonizing Wnt signaling in tumor cells" was invented by Vittoria Zinzalla (Vienna), Klaus-Peter Kuenkele (Perchtoldsdorf, Austria), Marie-Ange Buyse (Merelbeke, Belgium), Karen Cromie (Merelbeke, Belgium), Stephanie Staelens (Wevelgem, Belgium) and Beatrijs Strubbe (Oostakker, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides LRP5-binding polypeptides, and more specifically LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such...